SUMMARY Cardiac damage, consisting of mild diffuse myocarditis or severe inflammation and fibrosis of the conduction system or both, occurs in more than 70% of patients with idiopathic polymyositis. The lesions are strikingly similar to those detected in the infants of mothers with connective tissue diseases. In these infants the damage is associated with the transplacental passage of a maternal antibody to tissue ribonucleoproteins (anti-Ro). The same antibody was identified in 60% of 55 patients with polymyositis and in 69% (23/33) of those with associated cardiac damage including four with complete heart block. Forty five per cent of those patients who were anti-Ro seropositive had no clinical or electrocardiographic evidence of cardiac lesions.
Polymyositis is an inflammatory myopathy of unknown cause in which both hormonal and cellular abnormalities occur that may be related to a defect in immunoregulation.1 2 Skeletal muscle bears the brunt of the disease but the skin (dermatomyositis), heart, lungs, eyes, and kidneys may also be affected.2 Cardiac lesions are of particular importance both because of their frequency, which has only recently been fully documented, and because they are one of the leading causes of death in this disease.Ǹ umerous published reports (reviewed by Askari and Huettner3) show that approximately 70% of cases of polymyositis have evidence of cardiac damage with the conduction system showing the severest lesions in one third of those affected. Complete heart block can occur and may cause sudden unexpected death.5 In some cases, however, the lesions are confined entirely to the right or left bundle branch. The lesions found in the cardiac conduction system resemble those of the neonatal lupus syndrome,6 7 in which transplacental passage of a matemal autoantibody to tissue ribonucleoproteins (anti-Ro) seems to cause the damage.8 We Accepted for publication 11 Novenber 1986 serum samples from a group of 55 well defined cases of polymyositis for anti-Ro.
Patients and methods
We examined serum samples collected from 55 patients with polymyositis over the past 10 Sixteen patients were examined in the acute phase of the disorder, from six weeks to three months after onset. In six of them a serum sample was obtained Antibodies in cardiac damage before treatment and in the other 10 it was collected after steroids had been given. The remaining 39 cases had had chronic active polymyositis for four months to 15 years. Thirty six were taking prednisolone (5-10mg/day) and two of these were also on azothioprine (100mg/day). Three patients were taking no drugs. CARDIAC 
COMPLICATIONS
All patients had had electrocardiograms but most had no other cardiac investigations (table 1) .
The symptoms varied in degree from breathlessness on exertion to severe biventricular failure and included angina, dyspnoea, and palpitation; five patients had Adams-Stokes attacks. The most common electrocardiographic abnormalities were ST-T changes, right and left axis deviation, and abnormalities of the left atrial complex; but 13 patients had obvious evidence of conduction disorders-that is, five had complete heart block necessitating insertion of a pacemaker, four had right or left bundle branch block, and four had first degree heart block. Three of the patients with complete heart block died and in the two who came to necropsy there was almost complete fibrosis of the atrioventricular node with focal fibrosis of the bundle of His and the bundle branches; rare focal myocarditis was also present. The other two patients survived after the insertion of pacemakers. Two patients with right bundle branch block also died and necropsy confirmed focal fibrosis of the bundle, again accompanied by mild focal myocarditis and fibrosis.'0 CONTROL POPULATIONS Control serum samples were obtained from the following groups: (a) 100 normal healthy individuals; (b) 70 pregnant women attending an antenatal clinic; (c) 100 patients with other neuromuscular illnesses (multiple sclerosis, 60; myasthenia gravis, 25; alcoholic myopathy, five; intervertebral disc lesions, 10).
DETECTION OF ANTIBODIES
Serum samples were stored at -70°C until use and were confirmed by the demonstration of a complete reaction of identity with one of these known controls.
Positive anti-Ro antisera were obtained with the help of Dr P J Maddison, Dr G R V Hughes, and the Center for Disease Control, Atlanta; the CDC also supplied anti-La, anti-nRNP, and anti-Sm antisera (antisera to related non-histone extractable nuclear antigens).
The Ouchterlony plates were examined at 24, 48, 72, and 96 hours whereas the plates produced on counterimmunoelectrophoresis were left overnight at room temperature, washed in 5% citrate for four hours and then in phosphate buffered saline for 48 hours, and finally stained with Coomassie blue. 5, and 6 contain serafrom four cases ofpolymyositis with complete heart block. Wells 7-9 contain negative sera from other patients with polymyositis. ENA, extractable nuclear antigens from spleen. were anti-Ro positive. One of them was a man of 42 with dermatomyositis, who was anti-Ro seronegative when he was first examined three months after onset of disease. Two years later, when he complained of weakness and breathlessness and needed insertion of a pacemaker, he was seropositive. The fifth serum was anti-La positive; the presence of this antibody may, rarely, mask the simultaneous presence of anti-Ro. 6 Three of the four patients with first degree heart block had anti-Ro and two of the four with bundle branch block lesions associated with polymyositis were also anti-Ro seropositive. Of the 13 patients with conduction disorders, therefore, nine (possibly 10) were anti-Ro seropositive.
Tests for antibodies to the other non-histone nucleoprotein antigens La, nRNP, and SM showed that 13 of the anti-Ro seropositive patients were also positive for La antibodies while three patients had anti-La alone. Anti-nRNP was detectable in the four patients with the mixed connective tissue syndromes and anti-Sm in one other case. Two of the precipitating antibodies detected on the Ouchterlony plates could not be identified. Antinuclear antibodies were present at titres ranging from 1/64 (five cases) and 1/256 (three cases) to 1/1000 (eight cases). The serum samples with a titre of 1/1000 all gave a speckled appearance on immunofluorescence. No DNA antibodies were found and systemic lupus erythematosus was not diagnosed in any patient.
Discussion
We have shown in this study that 60% of a large group of patients with polymyositis and 69% of 
.bmj.com/ Downloaded from those with associated cardiac damage had a antibody to tissue ribonucleoproteins (anti-Ro). Anti-Ro seropositivity is found in 0-1% of the normal population'7 so that it was approximately 700 times more common in these patients with polymyositis and heart lesions, including conduction defects. Four of five patients with complete heart block had anti-Ro and the fifth had a high titre of anti-La (an antibody whose presence may interfere with detection of anti-Ro).'6 Ten cases who were anti-Ro seropositive did not have clinical or electrocardiographic signs of heart damage. However, more sensitive methods of cardiac investigation would undoubtedly have revealed abnormalities, as has been shown conclusively in other series3; also heart damage tends to occur late.5 Thus it is possible that the antibody is present for some time before the tissue injury develops.
Heart lesions were originally thought to be very uncommon in polymyositis, but since the 1970s a large number of clinical and necropsy reports have shown that from 70% to 100% of these patients will have evidence of cardiac damage and that cardiac failure is the third leading cause of death.3-5 A whole range of heart abnormalities has been reported and damage to the conducting system results in various degrees of heart block in up to a third of patients.3 Sudden unexpected deaths occur because of this damage and the cardiac lesions may progress even when the skeletal muscle lesions are improving.5 This indicates the importance of identifying a possible marker (such as anti-Ro) for heart injury.
The cardiac lesions found in this disorder, and especially those affecting the conduction tissue, are the same in site, degree, and pathological features as those found in isolated complete congenital heart block.6-8 10 This is why we thought that the same pathogenetic agent might be active in both conditions. There is strong evidence for the pathogenetic role of anti-Ro antibody in complete congenital heart block.8 16 18 19 Concentrations of the Ro antigen, which has recently been purified and 3~~~~~~~~~2 0 characterised' are highest in the heart and brain.
This may explain the susceptibility of cardiac tissue to such damage. Mothers of affected infants, however, do not appear to develop heart lesions.16 An explanation for this is that only developing cardiac tissue is susceptible. The results of our study, however, show that adult cardiac cells can be severely damaged by anti-Ro. This may be because whereas the majority of the mothers are otherwise healthy, patients with polymyositis have such severe hormonal and cellular immunological abnormalities that, in the presence of these immune aberrations, cardiac myocytes and Purkinje fibres can be attacked. The HLA groups may also be important: anti-Ro was found in two of 10 cases of polymyositis associated with HLA-DR3.2" Other factors are fluctuations in antibody titre, which we noticed in two of our cases, and the hormonal milieu. All our patients with dermatomyositis, of whom 65% were anti-Ro seropositive, were female. As in the large series of congenital heart block,8 some of our patients also had antibodies to other soluble cellular antigens. Thirteen of the anti-Ro seropositive patients also had anti-La. Four anti-Ro seronegative patients had anti-RNP and one had anti-Sm.
An unexpected finding in our control group was that one of the 25 patients with myasthenia gravis, all of whom had heart disease associated with their myasthenia, was anti-Ro positive. These cases of myasthenia gravis were the subject of a recent review (J A Aarli, 1986, personal communication, and22). A larger series is now being examined to see whether anti-Ro is associated with cardiac damage in this other immune-mediated muscle disease.
Finally, to some extent our findings resemble those recently reported for a similar autoantibody, anti-Jo-1.23 Anti-Jo-I was found in 25% of patients with myositis alone; however, 68% of patients with myositis and pulmonary damage were seropositive. Anti-Jo-l has therefore been suggested as a useful indicator of cryptogenic fibrosing alveolitis in patients with myositis.
Our results indicate that a specific autoantibody known to be associated with cardiac damage is 700 times more common in patients with polymyositis and heart involvement than in the general population. We suggest that this antibody (anti-Ro) is a marker for cardiac injury in myositis and may indeed be the pathogenetic agent. A search for antiRo in patients with myositis may help to identify those at risk of sudden death from cardiomyopathy.
